[1] Valle JW, Kelley RK, Nervi B, et al.Biliary tract cancer[J]. Lancet, 2021, 397(10272): 428-444. [2] Ouyang G, Liu Q, Wu Y, et al.The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Cancer, 2021, 127(13): 2238-2250. [3] Banales JM, Cardinale V, Carpino G, et al.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5): 261-280. [4] Valle JW, Lamarca A, Goyal L, et al.New Horizons for Precision Medicine in Biliary Tract Cancers[J]. Cancer Discov, 2017, 7(9): 943-962. [5] 李茂岚, 刘颖斌. 胆道恶性肿瘤临床研究进展与展望[J]. 中国实用外科杂志, 2020, 40(2): 167-170. [6] Lamarca A, Edeline J, Mcnamara MG, et al.Current standards and future perspectives in adjuvant treatment for biliary tract cancers[J]. Cancer Treat Rev, 2020, 84: 101936. [7] Park K, Kim KP, Park S, Chang HM.Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer[J]. Asia Pac J Clin Oncol, 2017, 13(1): 13-20. [8] Wang Y, Wen N, Wang S, et al.Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review[J]. BMC Cancer, 2023, 23(1): 378. [9] Oh D, He AR, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer [J]. NEJM Evid, 2022, 1(8): EVIDoa2200015. [10] Kelley RK, Ueno M, Yoo C, et al.Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10391): 1853-1865. [11] Kang J, Jeong JH, Hwang HS, et al.Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response[J]. Cancer Res Treat, 2020, 52(2): 594-603. [12] Piha-Paul SA, Oh DY, Ueno M, et al.Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies[J]. Int J Cancer, 2020, 147(8): 2190-2198. [13] Lin J, Yang X, Long J, et al.Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 414-424. [14] Zhang Q, Liu X, Wei S, et al.Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study[J]. Front Oncol, 2021, 11: 751391. [15] Zhang J, Zi R, Hu P, et al.COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma[J]. Front Pharmacol, 2025, 16: 1543193. [16] Oh SE, Oh MY, An JY, et al.Prognostic Value of Highly Expressed Type VII Collagen (COL7A1) in Patients With Gastric Cancer[J]. Pathol Oncol Res, 2021, 27: 1609860. [17] Ding C, Yu Z, Li X, et al.Collagen type VII α1 chain: A promising prognostic and immune infiltration biomarker of pancreatic cancer[J]. Oncol Lett, 2023, 25(2): 77. [18] Zhang H, Zheng Z, Zhang R, et al.SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters[J]. Cell Death Dis, 2021, 12(8): 731. [19] Hennedige TP, Neo WT, Venkatesh SK.Imaging of malignancies of the biliary tract- an update[J]. Cancer Imaging, 2014, 14(1): 14. [20] Banales JM, Marin JJG, Lamarca A, et al.Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(9): 557-588. [21] Yoon SB, Woo SM, Chun JW, et al.The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis[J]. Front Immunol, 2024, 15: 1321813. [22] Tomlinson JL, Valle JW, Ilyas SI.Immunobiology of cholangiocarcinoma[J]. J Hepatol, 2023, 79(3): 867-875. [23] Keenan BP, McCarthy EE, Ilano A, et al. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis[J]. Cell Rep, 2022, 40(12): 111384. [24] Fruman DA, Rommel C.PI3K and cancer: lessons, challenges and opportunities[J]. Nat Rev Drug Discov, 2014, 13(2): 140-156. [25] Cheng TC, Din ZH, Su JH, et al.Sinulariolide Suppresses Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase through the PI3K/AKT/mTOR Signaling Pathway in Human Bladder Cancer Cells[J]. Mar Drugs, 2017, 15(8): 238. |